Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors by Yun Zhang, Bhumsuk Keam, Jayesh Desai, Ben Markman, Shahneen Sandhu, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton

Get full text

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma by John F Thompson, Peter Hersey, Michael Millward, Paul Nathan, Weisan Chen, Ralph Venhaus, Andreas Behren, Cyril Fisher, Jonathan S Cebon, Martin Gore, Ian D Davis, Grant A McArthur, Euan Walpole, Mark Smithers, Vincenzo Cerundolo, P Rod Dunbar, Duncan MacGregor, Michael P N Findlay, T R Jeffry Evans, Jeremy Marsden, Angus G Dalgleish, Pippa G Corrie, Marples Maria, Margaret Brimble, Geoff Williams, Sintia Winkler, Heather M Jackson, Liliana Endo-Munoz, Candani S A Tutuka, Lloyd J Old, Dennis Haack, Eugene Maraskovsky

Get full text